Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates

Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced a conference call on February 26, 2021, at 8:00 a.m. ET to report its financial results for Q4 and FY 2020. The call will provide business updates, focusing on its antibody-drug conjugate pipeline. Mersana's lead candidate, upifitamab rilsodotin (XMT-1536), is in a Phase 1 study for ovarian cancer and NSCLC adenocarcinoma. The company is also advancing XMT-1592 and early-stage programs targeting various cancers using its proprietary ADC platforms.

Positive

• Mersana's lead candidate, upifitamab rilsodotin (XMT-1536), is in a Phase 1 expansion study for ovarian cancer and NSCLC adenocarcinoma.
• The company is advancing additional candidates, including XMT-1592 targeting NaPi2b-expressing tumors.

Negative

• None.

CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Friday, February 26, 2021 at 8:00 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2020 and provide business updates.

To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 2354447. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (XMT-1536, UpRi), is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:

Investor & Media Contact
Sarah Carmody, 617-844-8577
scarmody@mersana.com

FAQ

When is Mersana Therapeutics' conference call to discuss financial results for Q4 2020?

Mersana Therapeutics will host a conference call on February 26, 2021, at 8:00 a.m. ET.

What is Mersana Therapeutics' lead product candidate?

Mersana's lead product candidate is upifitamab rilsodotin (XMT-1536), targeting ovarian cancer and NSCLC adenocarcinoma.

Where can I access the live webcast for Mersana's conference call?

The live webcast can be accessed on the Investors & Media section of Mersana's website.

What other ADC product candidates is Mersana developing?

Mersana is also developing XMT-1592, XMT-1660, and XMT-2056, among others.